- Library Home /
- Search Collections /
- Open Collections /
- Browse Collections /
- UBC Faculty Research and Publications /
- Combination Therapy Using Inhalable GapmeR and Recombinant...
Open Collections
UBC Faculty Research and Publications
Combination Therapy Using Inhalable GapmeR and Recombinant ACE2 for COVID-19 Verma, Navin Kumar; Fazil, Mobashar Hussain Urf Turabe; Duggan, Shane; Kelleher, Dermot
Abstract
Here we report our perspective on applying GapmeR technology in combination with recombinant angiotensin-converting enzyme 2 (ACE2) in the treatment of COVID-19 patients. GapmeR is a cell-permeating antisense single-stranded DNA molecule that can be designed to specifically target intracellular severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Once internalized into host cells, such as lung alveolar cells, GapmeR molecules can bind to the viral RNA. This RNA/DNA hybrid will then be degraded by the RNase H enzyme abundantly present in the host cells. GapmeRs can be delivered to COVID-19 patients through inhalation or via nebulization. SARS-CoV-2- targeted GapmeR can also be given to frontline healthcare workers as a prophylactic protection. The recombinant ACE2 protein, the efficacy of which is being evaluated in clinical trials, will bind to the spike (S) glycoprotein of extracellular SARS-CoV-2 and potentially block viral infectivity. We propose that combining inhalable SARSCoV-2-targeted GapmeRs with recombinant ACE2 could provide a viable and rapidly implementable more effective therapeutic approach for eradicating SARS-CoV-2 and save millions of lives.
Item Metadata
Title |
Combination Therapy Using Inhalable GapmeR and Recombinant ACE2 for COVID-19
|
Creator | |
Publisher |
Frontiers
|
Date Issued |
2020-08-07
|
Description |
Here we report our perspective on applying GapmeR technology in combination with
recombinant angiotensin-converting enzyme 2 (ACE2) in the treatment of COVID-19
patients. GapmeR is a cell-permeating antisense single-stranded DNA molecule that
can be designed to specifically target intracellular severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2). Once internalized into host cells, such as lung alveolar
cells, GapmeR molecules can bind to the viral RNA. This RNA/DNA hybrid will then be
degraded by the RNase H enzyme abundantly present in the host cells. GapmeRs can
be delivered to COVID-19 patients through inhalation or via nebulization. SARS-CoV-2-
targeted GapmeR can also be given to frontline healthcare workers as a prophylactic
protection. The recombinant ACE2 protein, the efficacy of which is being evaluated
in clinical trials, will bind to the spike (S) glycoprotein of extracellular SARS-CoV-2
and potentially block viral infectivity. We propose that combining inhalable SARSCoV-2-targeted GapmeRs with recombinant ACE2 could provide a viable and rapidly
implementable more effective therapeutic approach for eradicating SARS-CoV-2 and
save millions of lives.
|
Subject | |
Genre | |
Type | |
Language |
eng
|
Date Available |
2021-03-31
|
Provider |
Vancouver : University of British Columbia Library
|
Rights |
Attribution 4.0 International
|
DOI |
10.14288/1.0396450
|
URI | |
Affiliation | |
Citation |
Verma NK, Fazil MHUT, Duggan SP and Kelleher D (2020) Combination Therapy Using Inhalable GapmeR and Recombinant ACE2 for COVID-19. Front. Mol. Biosci. 7:197
|
Publisher DOI |
10.3389/fmolb.2020.00197
|
Peer Review Status |
Reviewed
|
Scholarly Level |
Faculty; Postdoctoral
|
Copyright Holder |
The Authors
|
Rights URI | |
Aggregated Source Repository |
DSpace
|
Item Media
Item Citations and Data
Rights
Attribution 4.0 International